Haridwar Today

The Atrial Fibrillation market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atrial Fibrillation pipeline products will significantly revolutionize the Atrial Fibrillation market dynamics.

DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atrial Fibrillation market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Atrial Fibrillation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atrial Fibrillation Market Insights

Some of the key facts of the Atrial Fibrillation Market Report:

• The Atrial Fibrillation market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In October 2025, Pulse Biosciences, Inc. (NASDAQ: PLSE) is pioneering bioelectric medicine using its proprietary Nano-Pulse Stimulation (NPS) technology, focusing on immuno-oncology, dermatology, and cardiac ablation. Its Nanosecond Pulsed Field Ablation (nsPFA) system provides non-thermal cellular treatment methods and has received FDA Breakthrough Device Designation for its potential to revolutionize cardiac therapy.

• In October 2025, Kardium, a private medical device company focused on transforming atrial fibrillation (AF) treatment, announced the successful completion of its first commercial procedures using the Globe Pulsed Field System, its integrated mapping and ablation platform, following recent FDA approval.

• In September 2025, Kardium Inc. received FDA pre-market approval (PMA) for its Globe® Pulsed Field System and 510(k) clearance for the Globe® Introducer sheath and mapping software. The integrated platform supports high-density cardiac mapping and single-shot pulmonary vein isolation (PVI) for atrial fibrillation treatment using a single catheter.

• In July 2025, DeepQure announced that South Korea’s Ministry of Food and Drug Safety (MFDS) has granted approval for a clinical trial of its HyperQure™ RDM System, an innovative laparoscopic renal denervation (RDN) technology, for treating atrial fibrillation (AF). The study aims to assess the safety and effectiveness of laparoscopic RDN in patients with recurrent AF after pulmonary vein isolation (PVI) and those with resistant hypertension. Designed as a multicenter, prospective, single-arm, open-label exploratory trial, it will provide key insights into the potential of this novel approach.

• In March 2025, At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, Fretz et al. presented findings from a study examining the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on atrial fibrillation (AF) occurrence after hospitalisation for heart failure (HF). The onset of AF in HF patients is linked to higher morbidity and mortality rates. While GLP-1RA therapies have been shown to lower cardiovascular (CV) risk and enhance outcomes in patients with preserved-ejection fraction HF, their influence on AF incidence in HF populations has not yet been fully established.

• In January 2025, The initial phase of the ADVANTAGE AF clinical trial successfully met its safety and efficacy endpoints for treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE™ Pulsed Field Ablation System. Additionally, a sub-analysis from the OPTION clinical trial demonstrated consistent safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device when used after cardiac ablation, whether performed simultaneously (concomitant) or separately (sequential).

• In January 2025, CardioFocus, Inc., a medical device company specializing in ablation therapies for cardiac arrhythmias, has shared the 12-month outcomes from its ECLIPSE AF trial, published in Circulation: Arrhythmia & Electrophysiology. The study demonstrated that 90.2% of patients with paroxysmal atrial fibrillation (AF) remained free from clinically significant atrial arrhythmias one year after undergoing de novo pulmonary vein isolation (PVI). This result was achieved through the use of three commercially available contact-force sensing focal catheters in combination with the Centauri™ System’s advanced WAVE1™ pulsed field ablation (PFA) waveform.

• In January 2025, Boston Scientific Corporation (NYSE: BSX) has shared new data backing the use of both the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device at the AF Symposium 2025 during a late-breaking science session. The session also featured a predefined sub-analysis from the OPTION clinical trial, which expanded on the favorable primary endpoint outcomes previously presented at the American Heart Association 2024 conference and published in The New England Journal of Medicine. The analysis involved 1,600 atrial fibrillation patients who received device implantation either at the time of ablation or 90–180 days later, supporting the 36-month findings comparing the WATCHMAN FLX with direct oral anticoagulants (mostly DOACs)

• In January 2025, The initial phase of the ADVANTAGE AF clinical trial has achieved its safety and efficacy goals in treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE™ Pulsed Field Ablation (PFA) System. While the FARAPULSE PFA System is currently approved for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation—where irregular heart rhythms occur intermittently and typically resolve on their own—this study assessed its use for both PVI and posterior wall ablation (PWA) in those with persistent atrial fibrillation. This form of AF lasts longer than seven days and represents about 25% of all AF cases. The prospective, single-arm trial included 260 patients across 43 international sites who were unresponsive to at least one Class I or III anti-arrhythmic drug.

• According to recent secondary analyses, the estimated prevalence of atrial fibrillation in the United States ranges from approximately 2.7 to 6.1 million individuals.

• According to 2024 data from the National Heart, Lung, and Blood Institute (NHLBI), researchers found that approximately 2 million adults—representing 6.8% of the population studied—had atrial fibrillation, an irregular heart rhythm.

• In US, Atrial fibrillation prevalence increases significantly with age: it affects just 0.1% of individuals under 55, rises to 3.8% among those aged 60 and older, and reaches approximately 10% in people aged 80 and above. This age-related trend underscores the strong correlation between advancing age and atrial fibrillation risk.

• Secondary analysis indicates that atrial fibrillation is highly prevalent in the US, with an estimated lifetime risk of developing the condition affecting approximately 1 in 3 individuals over the age of 45.

• Recent secondary analysis indicates that approximately 1 in every 45 individuals in the UK is currently living with atrial fibrillation, highlighting its growing prevalence and public health impact.

• Epidemiological data from Japan reveal a higher prevalence of atrial fibrillation in men compared to women across all age groups. When stratified by decade, atrial fibrillation prevalence in men was 0.3% (ages 50–59), 2.4% (60–69), and 4.1% (70–79). In contrast, prevalence among women in the same age brackets was significantly lower at 0%, 0.3%, and 0.7%, respectively. These findings underscore a pronounced gender-based disparity in atrial fibrillation risk, particularly with advancing age.

• Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others

• Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others

• The Atrial Fibrillation epidemiology based on gender analyzed that Atrial fibrillation affects males more than females

Atrial Fibrillation Overview

Atrial Fibrillation is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain.

Get a Free sample for the Atrial Fibrillation Market Report –

https://www.delveinsight.com/report-store/atrial-fibrillation-market

Atrial Fibrillation Epidemiology

The Atrial Fibrillation epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atrial Fibrillation Epidemiology Segmentation:

The Atrial Fibrillation market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Prevalent Cases of Atrial fibrillation

• Diagnosed Prevalent Cases of Atrial fibrillation

• Gender-specific Diagnosed Prevalent Cases of Atrial Fibrillation

• Age-specific Diagnosed Prevalent Cases of Atrial Fibrillation

Download the report to understand which factors are driving Atrial Fibrillation epidemiology trends @ Atrial Fibrillation Epidemiological Insights

Atrial Fibrillation Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched during the study period. The analysis covers Atrial Fibrillation market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atrial Fibrillation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atrial Fibrillation Therapies and Key Companies

• RAPIBLYK (landiolol): AOP Orphan Pharmaceuticals

• Abelacimab: Novartis

• HBI-3000: HUYABIO International

• Research programme: Thryv Therapeutics Inc.

• CTP-Amio: Vivasc Therapeutics

• VE 1902: Verseon

• HBI-3000: HUYA Bioscience

• HSY 244: Novartis

• AGN-151607: AbbVie

• Asundexian: Bayer AG

• Inrhythm: InCarda Therapeutics, Inc.

To know more about Atrial Fibrillation treatment, visit @ Atrial Fibrillation Medications

Atrial Fibrillation Market Drivers

• Rising prevalence of atrial fibrillation: An aging population, increasing obesity, hypertension, diabetes, heart failure, and improved survival after cardiovascular events are contributing to the growing AF patient pool.

• Increasing risk of AF-related stroke: The substantial risk of thromboembolic stroke associated with AF is driving demand for effective anticoagulation and stroke-prevention therapies.

• Growing adoption of novel anticoagulants: Direct oral anticoagulants (DOACs) and emerging Factor XI/FXIa inhibitors are expanding treatment options, particularly for patients seeking safer stroke-prevention approaches.

• Improved disease awareness and diagnosis: Greater awareness, screening, ECG monitoring, and digital technologies such as wearable devices are supporting earlier detection of previously undiagnosed AF.

• Strong clinical pipeline and unmet needs: Development of therapies with improved safety, reduced bleeding risk, and better efficacy is expected to create new opportunities in the AF market.

Atrial Fibrillation Market Barriers

• Underdiagnosis and delayed detection: A substantial proportion of AF cases remain undiagnosed, particularly among high-risk populations, limiting timely initiation of treatment.

• Bleeding concerns with anticoagulation: Fear of bleeding among physicians and patients remains an important barrier to appropriate anticoagulant use and can result in undertreatment.

• Poor treatment adherence: Forgetfulness, polypharmacy, inadequate patient education, and concerns about adverse effects can contribute to nonadherence and reduced treatment effectiveness.

• High cost and limited access: The cost and availability of newer anticoagulants, along with unequal healthcare access, can restrict adoption, particularly in resource-constrained markets.

• Generic competition: Increasing availability of inexpensive generic rate-control, rhythm-control, and anticoagulant therapies can create pricing pressure and make market entry challenging for newer branded therapies.

Scope of the Atrial Fibrillation Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others

• Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others

• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies

• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Atrial Fibrillation Unmet Needs, KOL’s views, Analyst’s views, Atrial Fibrillation Market Access and Reimbursement

Discover more about therapies set to grab major Atrial Fibrillation market share @ Atrial Fibrillation Treatment Landscape

Table of Contents

1. Atrial Fibrillation Market Report Introduction

2. Executive Summary for Atrial Fibrillation

3. SWOT analysis of Atrial Fibrillation

4. Atrial Fibrillation Patient Share (%) Overview at a Glance

5. Atrial Fibrillation Market Overview at a Glance

6. Atrial Fibrillation Disease Background and Overview

7. Atrial Fibrillation Epidemiology and Patient Population

8. Country-Specific Patient Population of Atrial Fibrillation

9. Atrial Fibrillation Current Treatment and Medical Practices

10. Atrial Fibrillation Unmet Needs

11. Atrial Fibrillation Emerging Therapies

12. Atrial Fibrillation Market Outlook

13. Country-Wise Atrial Fibrillation Market Analysis (2020–2034)

14. Atrial Fibrillation Market Access and Reimbursement of Therapies

15. Atrial Fibrillation Market Drivers

16. Atrial Fibrillation Market Barriers

17. Atrial Fibrillation Appendix

18. Atrial Fibrillation Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/